FDA Posts ICH Q4B Analytical Guidances - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Posts ICH Q4B Analytical Guidances


ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration (Rockville, MD, www.fda.gov) has published a draft guidance, Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC), available online at http://www.fda.gov/cder/guidance/7386dft.htm. The guidance describes the  International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH, www.ich.org) Q4B draft standard (as revised in June), outlining the procedure for "acceptance by regulatory authorities of pharmacopoeial" standards for APAC (analytical procedures and/or acceptance criteria).  (ICH's  Q4 activities focus on harmonizing the requirements of the world's pharmacopoeias.)

At the same time, FDA published the first specific draft guidance under the RAAPAC procedure, Annex 1:  Residue on Ignition/Sulphated Ash General Chapter Analytical Procedures and/or Acceptance Criteria (APAC) (http://www.fda.gov/cder/guidance/7387dft.htm).

The guidance describes the reconciliation (via specification of sample size and a caveat on test-furnace calibration) of US Pharmacopeia, European Pharmacopoeia, and Japanese Pharmacopoeia testing procedures for residual ash, an index of the inorganic impurities in an organic sample.

The eight-page guidance and four-page annex were posted jointly by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here